近日,北京海润天睿律师事务所作为发行人律师助力爱美客技术发展股份有限公司(以下简称“爱美客”)成功上市深圳证券交易所创业板,本次IPO共募集约5.2亿美金。

爱美客主要从事生物医用软组织修复材料的生产、研发和销售,是首家取得国家药监局批准用于面部软组织修复的注射用透明质酸钠医疗器械产品注册证书的国内企业。爱美客是国家级高新技术企业,建有生物可降解新材料北京市工程实验室,作为牵头单位参与了国家科学技术部“十三五”规划国家重点研发计划“新型颌面软硬组织修复材料研发”项目。

海润天睿团队由合伙人李冬梅律师牵头领导。

本次IPO的承销商为中信证券股份有限公司。

Hairun advises IMEIK on $520mln ChiNext IPO 

Hai Run Law Firm has advised IMEIK Technology Development (IMEIK) on its $520 million IPO on the Shenzhen Stock Exchange’s ChiNext market. 

IMEIK is a national high-tech enterprise focusing on the research and development, manufacture and sales of biomedical materials. It is the first domestic enterprise that has obtained the registration certificate of injected sodium hyaluronate for facial soft tissue repair approved by the State Administration of Food and Drug Administration. 

The Hai Run team was led by partner Li Dongmei, while the underwriter was CITIC Securities.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.